One Amgen Center Drive
At Amgen, our mission—to serve patients—drives all that we do. This sense of shared purpose has allowed us to become one of the world’s leading biotechnology companies as we continue to launch new medicines at unprecedented rates and reach millions of patients worldwide.
We collaborate with world-class talent, utilize the industry’s largest toolkit of modalities, and leverage industry-leading partnerships and state-of-the-art technology to develop new processes and products that can turn the tide of serious, life-interrupting illnesses.
As a values-based organization, we aim to make a positive impact on the world. From investments in education to inspire future generations of scientists, to rewarding our colleagues with robust family-centered benefits, we believe in making a difference in the lives of our patients, staff and communities.
At Amgen, we believe in the power of tomorrow and it shows.
Discover what Amgen can do for you by visiting careers.amgen.com.
For more information, visit
www.amgen.com, LinkedIn and follow us on www.twitter.com/amgencareers.
Tweets by Amgen
The Amgen Difference
1951 articles with Amgen
When it comes to specific attributes, having the opportunity to do interesting and meaningful work, securing a competitive salary and having access to quality health benefits were the most important. Here are some differences when it comes to generational priorities.
Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) approved Amgen's Supplemental Biologics License Application (sBLA) for Nplate® (romiplostim) to include new data in its U.S. prescribing information showing sustained platelet responses in adults with immune thrombocytopenia (ITP), a rare, serious autoimmune disease characterized by low platelet counts.
EVENITY® (Romosozumab) Receives Positive CHMP Opinion For The Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fracture
Amgen and UCB announced that following a re-examination procedure, the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending Marketing Authorization for EVENITY® for the treatment of severe osteoporosis in postmenopausal women at high risk of fracture and with no history of myocardial infarction or stroke.
Amgen (NASDAQ:AMGN) today announced the expansion of Myeloma MVP™, a national initiative to help myeloma patients and their care teams create their Most Valuable Plan.
10/14/2019What makes an organization a desirable employer? Do they need to be a large company with a recognizable name? Should the organization pay their employees more than others?
The Amgen Foundation today announced the launch of the Amgen Biotech Experience (ABE) program in Pittsburgh, Pa.
Health Canada Approves EVENITY For the Treatment of Osteoporosis in Postmenopausal Women at High Risk for Fracture
Today Amgen Canada announced that EVENITY® (romosozumab) is now available in Canada for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture.
10/1/2019Fall frenzy is heading our way! Check out the top companies who are looking for candidates like you right now!
Amgen Announces New Clinical Data Evaluating Novel Investigational KRAS(G12C) Inhibitor In Patients With Solid Tumors At ESMO 2019
Responses Seen in Multiple Tumor Types With KRAS G12C Mutation
Heart Attack Survivors Are Taking Steps To Reduce Their Cardiovascular Risk. But Are They The Right Ones?
This World Heart Day, Amgen is Releasing Results of a Global Survey of 3,200 Heart Attack Survivors Conducted Across 13 Countries Close to Half of Survivors Are Not Monitoring Their Cholesterol Regularly
According to the second biennial 2019 Life Sciences Ideal Employer Report by BioSpace, the top three most important attributes cited by life sciences professionals around the world are the opportunity to do interesting and meaningful work, a competitive salary and health benefits.
BioSpace, the leader in life sciences news and careers, today announced that Genentech, Pfizer, Merck, Amgen and Novartis landed in the top five spots of their latest Ideal Employer report.
Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the European Society for Medical Oncology (ESMO) 2019 Congress on Saturday, Sept. 28, at 10 a.m. PT.
Amgen Announces Positive Results From Two Phase 3 BLINCYTO® (blinatumomab) Studies In Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia
Amgen (NASDAQ:AMGN) today announced that the results of a prespecified interim analysis of an open-label, randomized, controlled global multicenter Phase 3 trial (20120215) showed that the primary endpoint of event-free survival was met.
The collaborative study of regulatory-grade real world evidence in cardiovascular medicine demonstrates data and technologies to support high credibility clinical assertions
Amgen (NASDAQ:AMGN) today announced that new data from its oncology pipeline and marketed product portfolio will be presented at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain, Sept. 27-Oct. 1, 2019.
9/16/2019Last week was a busy one for clinical trial results, particularly with the European Committee for Treatment and Research in Multiple Sclerosis 2019 Congress going on. Here’s a look at some of the top clinical trial stories.
Amgen will present at the Bank of America Merrill Lynch Global Healthcare Conference at 9:45 a.m. British Summer Time on Wednesday, Sept. 18, 2019, in London.
Amgen Announces Phase 3 CANDOR Study Combining KYPROLIS® (carfilzomib) And DARZALEX® (daratumumab) Meets Primary Endpoint Of Progression-Free Survival
Amgen (NASDAQ:AMGN) today announced the Phase 3 CANDOR study evaluating KYPROLIS® (carfilzomib) in combination with dexamethasone and DARZALEX® (daratumumab) (KdD) compared to KYPROLIS and dexamethasone alone (Kd) met its primary endpoint of progression-free survival (PFS).
Amgen (NASDAQ:AMGN) today announced that new data from its oncology portfolio and pipeline will be presented at the 17th International Myeloma Workshop (IMW) 2019 in Boston, Sept. 12-15, 2019.